

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

16 December 2021 (16.12.2021)



(10) International Publication Number

WO 2021/252718 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) A61K 45/06 (2006.01)

A61K 31/4706 (2006.01) A61P 37/02 (2006.01)

A61K 31/573 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2021/036740

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

10 June 2021 (10.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202011024586 11 June 2020 (11.06.2020) IN

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: SCHIEVEN, Gary L.; 519 Bergen

Street, Lawrenceville, New Jersey 08648 (US). DUDHGAONKAR, Shailesh; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore Karnataka 560 099 (IN).

(74) Agent: GREENBLATT, Gary D. et al.; Bristol-Myers

Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TLR7 INHIBITOR IN COMBINATION WITH PREDNISOLONE OR HYDROXYCHLOROQUINE FOR TREATING CUTANEOUS LUPUS ERYTHEMATOSUS

(57) Abstract: Disclosed is method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine or a pharmaceutically acceptable salt thereof.



WO 2021/252718 A1

**TLR7 INHIBITOR IN COMBINATION WITH PREDNISOLONE
OR HYDROXYCHLOROQUINE FOR TREATING CUTANEOUS
LUPUS ERYTHEMATOSUS**

CROSS REFERENCE

This application claims the benefit of Indian Provisional Application Serial No.
5 202011024586, filed June 11, 2021, which is incorporated herein in its entirety.

DESCRIPTION

The present invention generally relates a method of treating a patient having
cutaneous lupus erythematosus, comprising administering to said patient a therapeutically
10 effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in
combination with a therapeutically effective dose of a second agent selected from
prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof

BACKGROUND OF THE INVENTION

15 Toll-like receptors (TLRs) are a family of pattern recognition receptors that
recognize highly conserved components of diverse pathogens and induce innate and
adaptive immune responses (Akira S, Takeda K, Kaisho T, *Nat Immunol.*
2001;2:675–680; Pandey S, Agrawal DK., *Immunol Cell Biol.* 2006;84:333–341; Kawai
T, Akira S. *J Biochem.* 2007;141:137–145). TLR7 and TLR8 have been shown to be
20 expressed in endosomal compartments and to recognize ssRNA molecular patterns.
TLR7 is expressed in B cells and plasmacytoid dendritic cells (pDC); TLR8 is expressed
in monocytes and myeloid dendritic cells (mDC) (Chuang TH, Ulevitch RJ. *Eur*
Cytokine Net. 2000;11:372–378; Iwasaki A, Medzhitov R. *Nat Immunol.* 2004;5:987–
995).

25 Cutaneous lupus erythematosus (CLE) is a skin disorder which can occur as
isolated skin manifestation or with concomitant systemic lupus erythematosus (SLE)
(Okon LG, Werth VP. *Best Pract Res Clin Rheumatol.* 2013;27:391–404; Cohen MR,
Crosby D. *J Rheumatol.* 1994;21:1665–1669).

CLE is often associated with the presence of autoantibodies with varying
30 frequency. Similar to SLE, Type I Interferon (IFN) dysregulation is proposed to be a key
pathogenic driver in CLE. CLE patients often present with IFN signature in blood and in
skin lesions, with blood IFN signature correlating with skin disease activity score

(Braunstein I, Klein R, Okawa J, et al., *Br J Dermatol.* 2012;166:971–975; Meller S, Winterberg F, Gilliet M, et al., *Arthritis Rheum.* 2005;52:1504–1516, Wenzel J, Zahn S, Mikus S, et al., *Br J Dermatol.* 2007;157:752–757).

Treatment with sifalimumab (anti-IFN α mAb) and anifrolumab (anti-IFNAR mAb) showed an improvement of skin disease activity scores in SLE patients presenting with cutaneous disease in Phase II clinical trials further supporting the contribution of Type I IFN to the pathogenesis of CLE (Furie R, Khamashta M, Merrill JT, et al. *Arthritis Rheumatol.* 2017;69:376–86; Petri M, Wallace DJ, Spindler A, et al. *Arthritis Rheum.* 2013;65:1011–1021). Plasmacytoid dendritic cells (pDCs) are specialized cells that accumulate in the skin of CLE patients and account for 5-10% of the immune infiltrate and have been proposed to be the major source of Type I IFN in CLE skin lesions. The pDCs robustly secrete IFN α in response to TLR7 and TLR9 stimulation by nucleic acid ligands, while TLR8 induces a variety of myeloid cells to produce proinflammatory cytokines such as TNF α and IL-6 (Siegal FP, Kadowaki N, Shodell M, et al. *Science* 1999;284:1835–1837; Tomasini D, Mentzel T, Hantschke M, et al., *J Cutan Pathol.* 2010;37:1132–1139; Vermi W, Lonardi S, Morassi M, et al., *Immunobiology* 2009;214:877–86).

Apoptotic debris induced by ultra-violet radiation, a well-known environmental trigger of CLE, leads to the accumulation of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) fragments that would activate TLR7 and TLR9 respectively, leading to pDC activation and Type I IFN production (Wenzel J, Proelss J, Wiechert A, et al., *J Am Acad Dermatol.* 2007;56: 648–650).

New methods of treating CLE are desired.

Disclosed herein are methods of treating cutaneous lupus erythematosus, comprising administering to a patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof.

Also disclosed herein are methods of treating cutaneous lupus erythematosus, comprising administering to a patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof.

SUMMARY OF THE INVENTION

The present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination
5 with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.

The present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination
10 with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof.

The present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination
15 with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof.

These and other features of the invention will be set forth in expanded form as the disclosure continues.

20 BRIEF DESCRIPTION OF THE DRAWINGS

The invention is illustrated by reference to the accompanying drawings described below.

FIG. 1 shows the inhibition of cutaneous lesions following treatment with either Compound (I) or prednisolone in female MRL/lpr mice. A: Neck lesions; B: Head
25 lesions; C: Face lesions; D: Ear lesions; E: Total lesions.

FIG. 2 shows the reduction of erythema of cutaneous lesions treatment with either Compound (I) or prednisolone in female MRL/lpr mice. A: Neck Erythema; B: Ear Erythema; C: Total Erythema.

FIG 3 shows the inhibition of circulating antibody titers including anti-dsDNA, anti-smRNP and anti-Ro antibody titers following treatment with either Compound (I) or
30 prednisolone.

FIG 4 shows reduction in the proteinuria and urinary NGAL following treatment

with either Compound (I) or prednisolone.

FIG 5 shows Compound (I) inhibits TLR7-induced IL-6 in an ex vivo settings following treatment with either Compound (I) or prednisolone.

FIG 6 shows the total lesions for the female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 7 shows the neck erythema score for female MRL/lpr mice treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 8 shows the ear erythema score for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 9 shows the total erythema score for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 10 shows the proteinuria levels for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 11 shows the urinary NGAL levels for female MRL/lpr mice in established disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 12 shows the total lesions for the female MRL/lpr mice in advanced disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 13 shows the neck erythema score for female MRL/lpr mice treated with vehicle, Compound (I), prednisolone, and Compound (I) + prednisolone.

FIG 14 shows the neck erythema score for female MRL/lpr mice treated with vehicle, hydroxychloroquine, and Compound (I) + hydroxychloroquine.

FIG 15 shows the ear erythema score for female MRL/lpr mice in advanced disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

FIG 16 shows the total erythema score for female MRL/lpr mice in advanced


disease treated with vehicle, Compound (I), prednisolone, hydroxychloroquine, Compound (I) + prednisolone, and Compound (I) + hydroxychloroquine.

DEFINITIONS

5 In order that the present description may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

A “TR7 inhibitor” inhibits the function of TLR7. TLR7 inhibitors can associate with TLR7 reversibly or irreversibly, and include antibodies, small molecules, and
10 millimolecular compounds.

The compound of Formula (I) is a TLR7 inhibitor and has the structure:




The chemical name for the compound of Formula (I) is 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)acetamide.

15 The discovery and synthesis of the compound of Formula (I) is described in WO 2018/005586 A1.

Prednisolone is a corticosteroid drug having the chemical name: 11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a] phenanthren-3-one. Prednisolone can be orally administered
20 as a tablet, an orally disintegrating tablet, a solution, or a suspension. Ophthalmic prednisolone is available as a solution (liquid) and a suspension (eye drops). Prednisolone is available as a sodium salt. Prednisolone can also be administered as the prodrug prednisone. As used herein “prednisolone” includes both prednisolone and prednisone. As used herein “Pred” refers to prednisolone.

25 Hydroxychloroquine has the structure



As used herein "HCQ" refers to hydroxychloroquine. Hydroxychloroquine is used to treat or prevent auto-immune diseases including lupus and rheumatoid arthritis. It can reduce skin problems in lupus, including cutaneous lupus erythematosus and prevent swelling/pain in arthritis. Hydroxychloroquine is available as a sulfate salt in which
5 200 mg of the sulfate salt is equal to 155 mg of the base.

Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms
10 shall include pluralities and plural terms shall include the singular.

The terms "treat," "treating," and "treatment," as used herein, refer to any type of intervention or process performed on, or administering an active agent to, the patient with the objective of reversing, alleviating, ameliorating, inhibiting, or slowing down or preventing the progression, development, severity or recurrence of a symptom,
15 complication, condition or biochemical indicia associated with a disease. Treatment includes therapeutic treatment and prophylactic or preventative measures, wherein the object is prevent or lessen the targeted condition or disorder.

The term "therapeutically effective amount" or "therapeutically effective dosage" of a drug or therapeutic agent refers to an amount of a drug effective to treat a disease or disorder in a patient. In certain embodiments, an effective amount refers to an amount effective, at dosages and for period of time necessary, achieve the desired therapeutic or prophylactic result. The ability of a therapeutic agent to promote disease regression or inhibit the development or recurrence of the disease can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials,
20 in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in *in vitro* assays.

Therapeutically effective amounts of a TLR7 inhibitor, prednisolone, and hydroxychloroquine may vary according to factors such as the disease state, age, sex, and weight of the patient, and abilities of the TLR7 inhibitor, prednisolone, and

of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof; and a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.

5 One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the
10 compound of Formula (I).

One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisone or a pharmaceutically acceptable salt thereof.
15 Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).

One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a
20 therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).

One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose
25 of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).

30 One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a

therapeutically effective dose of a second agent selected from prednisolone or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).

5 One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered
10 simultaneously with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).

One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a
15 therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is administered prior to the administration of the second agent. Also included in this embodiment is a method in which the TLR7 agent is
20 administered after the second agent. Additionally, included in this embodiment is a method in which TLR7 inhibitor is the compound of Formula (I).

One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a
25 therapeutically effective dose of a second agent selected from prednisolone or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is administered prior to the administration of the second agent. Also included in this embodiment is a method in which the TLR7 agent is administered after
30 the second agent. Additionally, included in this embodiment is a method in which TLR7 inhibitor is the compound of Formula (I).

One embodiment provides a method of treating a patient having cutaneous lupus

erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein said second agent is administered
5 sequentially with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is administered prior to the administration of the second agent. Also included in this embodiment is a method in which the TLR7 agent is administered after the second agent. Additionally, included in this embodiment is a method in which TLR7 inhibitor is the compound of Formula (I).

10 In one embodiment, a therapeutically effective dose of the compound of Formula (I) is in the range of 0.1 to 100 mg.

In one embodiment, a therapeutically effective dose of the compound of prednisolone is in the range of 0.5 to 50 mg.

15 In one embodiment, a therapeutically effective dose of the compound of hydroxychloroquine is in the range of 1 to 20 mg.

The therapeutically effective dose of the TL7 inhibitor can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.

20 The therapeutically effective dose of prednisolone can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.

The therapeutically effective dose of hydroxychloroquine can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.

25 In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a single daily dose.

In one embodiment, the therapeutically effective dose of the compound of Formula (I) is administered as a single daily dose.

30 In one embodiment, the therapeutically effective dose of prednisolone is administered as a single daily dose.

In one embodiment, the therapeutically effective dose of hydroxychloroquine is administered as a single daily dose.

In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a single daily dose and the therapeutically effective dose of the second agent selected from prednisolone and hydroxychloroquine is administered as a single dose. Included in this embodiment, is a method in which the TLR7 inhibitor and the second agent are administered once a day, wherein the TLR7 inhibitor and the second agent are administered simultaneously, or the TLR7 inhibitor is administered immediately before or after the administration of the second agent. Also include in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I). Additionally, included in this embodiment is a method in which the second agent is prednisolone. Further, included in this embodiment is a method in which the second agent is hydroxychloroquine.

In one embodiment, a therapeutically effective dose of prednisolone is administered as a single daily dose.

In one embodiment, a therapeutically effective dose of hydroxychloroquine is administered as a single daily dose.

In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a twice daily dose and the therapeutically effective dose of the second agent is administered either one or twice daily dose. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).

In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a twice daily dose and the therapeutically effective dose of the second agent selected from prednisolone and hydroxychloroquine is administered as a twice dose. Included in this embodiment, is a method in which the TLR7 inhibitor and the second agent are administered twice a day, wherein the TLR7 inhibitor and the second agent are administered simultaneously twice daily, or the TLR7 inhibitor is administered immediately before or after the administration of the second agent twice daily. Also include in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I). Additionally, included in this embodiment is a method in which the second agent is prednisolone. Further, included in this embodiment is a method in which the second agent is hydroxychloroquine.

In an another embodiment, the method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective

dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, and in combination with one or more additional third agents. Examples of suitable third agents include

5 corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as dexamethasone; antiproliferative agents such as methotrexate,

10 leflunomide, FK506 (tacrolimus, PROGRAF®); cytotoxic drugs such as azathioprine and cyclophosphamide; TNF- α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof. The above third agents, when employed in combination with the combinations of Compound (I) and the second agent, may be used, for example, in those amounts indicated in the

15 *Physicians' Desk Reference* (PDR) or as otherwise determined by one of ordinary skill in the art. In the methods of the present invention, the one or more third agents may be administered prior to, simultaneously with, or following the administration of Compound (I) or the second agent.

20 Cutaneous Lupus Erythematosus Study in Mice

Materials and Methods

All the animal experimental procedures were reviewed and approved by the Institutional Animal Ethics Committee (IAEC) and conducted in accordance with procedures set by the Committee For The Purpose of Control and Supervision on

25 Experiments on Animals (CPCSEA). Mice were group housed in Syngene Laboratory Animal Research Facility (SLAR, Bangalore India; AAALAC accredited), and maintained under normal 12 h light /12 h dark cycle with ad libitum access to food and water. At the end of the studies, animals were euthanized by CO₂ asphyxiation for plasma and tissue collection.

30

Cutaneous Model of Lupus

Female MRL/lpr mice of 12 to 14 weeks of age were screened and randomized

based on the titers of anti-dsDNA antibodies and urinary neutrophil gelatinase-associated lipocalin (NGAL). Mice were treated orally, once daily for 8 weeks with vehicle (10% ethanol; 45% PEG 300; 5% Pluronic F-68; 40% 20 mM citrate buffer) or different doses of test compound (Compound (I)) or reference (prednisolone) compound. The effect of vehicle, test or reference compounds on cutaneous disease severity were assessed by evaluating skin lesions on the neck, head, face and ear separately. The severity of skin lesions was assessed every week by counting the number of lesions as well as erythema (on the scale of 0 to 4, considering zero - none; 1 - mild, 2 - moderate, 3 - moderate to severe and 4 - very marked and severe). Total erythema was derived by adding the erythema scores of neck, head, ear and face lesions. Since female MRL/lpr mice also develop nephritis in addition to cutaneous lesions, the effect of vehicle, test or reference compounds on renal disease were evaluated by measuring proteinuria, urinary NGAL and autoantibody titers like anti-Ro, anti-smRNP and anti-dsDNA Ab titer. One week before termination of the experiment, mice were bled at various time points to capture the complete pharmacokinetic profile of the test or reference compound and also the extent of inhibition of gardiquimod-induced IL-6 in an ex vivo whole blood assay. Spleen samples were taken at the end of the study to measure the impact of treatment on IL-6 and IFN α -producing cell population by flow cytometry. Blood samples were analyzed for gene expression by qPCR and for TLR7 target coverage utilizing an ex vivo blood assay of gardiquimod induced IL-6 production. Statistical analysis was done using one-way ANOVA with Dunnett's test to calculate the significance of test or reference compound treated groups vs. vehicle control group. Percent reduction in disease severity was calculated for each parameter, for test or reference compound treated groups vs. vehicle control group.

25

Inhibition of Cutaneous manifestations in MRL/lpr Model of Lupus

Female MRL/lpr mice develop cutaneous lesions in a spontaneous manner, making this a widely accepted preclinical murine model of cutaneous lupus. In addition to cutaneous manifestations, these mice also showed kidney injury. Compound was investigated for its effects on both skin lesions and on kidney injury markers in this model. In this study, mice were randomized based on urinary NGAL and anti-dsDNA Ab titer. Immediately after recruitment, mice were treated with Compound (I) and

30

prednisolone for 8 weeks.

Figure 1: Inhibition of cutaneous lesions in female MRL/lpr mice following treatment with Compound (I). Mice were dosed orally for 8 weeks. . Skin lesions were then assessed on neck (A), head (B), face (C), and ear (D). The impact of treatment on the total lesions were also represented by adding the number of lesions present on face, neck, head, and ear. (E) Data are from one experiment with 13 to 15 mice per group. *P < 0.01, **P < 0.001, ***P < 0.0001 versus vehicle by two-way ANOVA with a Bonferroni test.

Figure 2: Treatment of female MRL/lpr mice with Compound (I) suppressed erythema of cutaneous lesions. Mice were dosed orally for 8 weeks. Erythema of skin lesions were assessed on neck (A) and ear (B). The impact of treatment on the total erythema was also represented by assessing the erythematous score of skin lesions present on back, face, neck, ear and head (C). Data are from one experiment with 13 to 15 mice per group. *P < 0.01, **P < 0.001, ***P < 0.0001 versus vehicle by two-way ANOVA with a Bonferroni test.

Figure 3: Inhibition of autoantibodies in female MRL/lpr mice treated with Compound (I). Mice were dosed orally for 8 weeks with respective treatment. Following 8 weeks of dosing, anti-dsDNA (A) and anti-Ro (B) and anti-smRNP antibody titers (C) were assessed. Data are from one experiment with 13 to 15 mice per group. Percent inhibition relative to the vehicle group is shown above each bar. *P < 0.01, **P < 0.001, ***P < 0.0001 versus vehicle by one-way ANOVA with a Dunnett's test.

Figure 4: Inhibition of kidney injury markers in female MRL/lpr mice treated with Compound (I). Mice were dosed orally for 8 weeks with respective treatment. Following 8 weeks of dosing, proteinuria (A) and urinary NGAL (B) were assessed. Data are from one experiment with 13 to 15 mice per group. Percent inhibition relative to the vehicle group is shown above each bar. *P < 0.01, **P < 0.001, ***P < 0.0001 versus vehicle by one-way ANOVA with a Dunnett's test.

Figure 5: Compound (I) inhibited TLR7-dependent IL-6 induction in an ex vivo assay in female MRL/lpr model of lupus. Mice were dosed orally for 7 weeks with respective treatment. Following 7 weeks of dosing, mouse whole blood was drawn at different time points and challenged with gardiquimod for 16 to 18 hours. IL-6 inhibition was assessed by ELISA. Data are from one experiment in which measurements were made in three mice per group per time point.

Treatment with Compound (I) improved survival of mice in Female MRL/lpr model of lupus compared to vehicle

TABLE 1

Treatment Groups	Dose (mg/kg)	% Survival
Vehicle	NA	87
Compound (I)	0.005	87
	0.02	93
	0.25	100
	0.75	100
Prednisolone	10	100

Abbreviation: NA, not applicable.

5

The data in Table 1 shows that treatment with Compound (I) improved survival of the mice in this study. Whereas only 87% of vehicle mice survived for 8 weeks, mice receiving doses of 0.25 and 0.75 mg/kg of Compound (I) achieved 100% survival.

As shown in Figure 1, Compound (I) showed significant and robust dose-dependent suppression of cutaneous manifestations as assessed by measuring the number of lesions on face, neck, head, and ear. The impact of treatment on the total lesions were also represented by adding the number of lesions present on face, neck, head, and ear. Furthermore, the effect of Compound (I) was also evaluated by assessing the erythema on neck and ear and represented individually. Additionally, skin lesions were also evaluated for total erythema after assessing the erythema of skin lesions present on back, face, neck, ear and head. A significant reduction in the erythema upon treatment with Compound (I) was observed Figure 2. Representative images of lesions in mice treated with Compound (I) and vehicle mice at the 8 week time point are shown in Figure 3.

Dose-dependent inhibition of cutaneous lesions including number of lesions as well as erythema of lesions was observed with treatment with Compound (I) in mice. Greater efficacy was observed with 0.25 mg/kg and 0.75 mg/kg doses of Compound (I). These two doses resulted in improved survival, 100% versus 87% survival of vehicle treated mice. At these doses, Compound (I) showed suppression of lupus nephritis as assessed by kidney injury markers like proteinuria and urinary NGAL. Additionally, at these two doses, Compound (I) showed significant suppression of anti-dsDNA, anti-RO

and anti-smRNP auto-antibody titers and inhibited Type I IFN response gene expression.

Combination Studies

TABLE 2

No.	Treatment	Dose (mg/kg)	n
1	Vehicle	5ml/kg, qd	15
2	Compound (I)	0.25	15
3	Prednisolone	1	15
4	HCQ	100	15
5	Compound (I) + Prednisolone	0.25 + 1	15
6	Compound (I) + HCQ	0.25 + 100	15
7	Prednisolone	10	15

5

1. Combination Studies of Compound (I) with Prednisolone and Compound (I) with hydroxychloroquine (HCQ) in MRL/lpr Model of Lupus – Established Disease

Female MRL/lpr mice of 15 weeks of age were treated for 5 weeks. Mice were recruited when they showed group average of total skin lesions score as 1.5 to 2. Total skin lesions score includes cumulative score of Neck/Back, Face, Head and Ear lesions

10

TABLE 3

No.	Treatment	Dose (mg/kg)	% Survival
1	Vehicle	5ml/kg, qd	93.3
2	Compound (I)	0.25	100
3	Prednisolone	1	93.3
4	HCQ	100	93.3

5	Compound (I) + Prednisolone	0.25 + 1	100
6	Compound (I) + HCQ	0.25 + 100	100
7	Prednisolone	10	93.3

Figure 6: Treatment with Compound (I) suppressed the total number of cutaneous lesions in mice in established disease compared to treatment with vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of cutaneous lesions but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.

Figure 7: Treatment with Compound (I) suppressed erythema of cutaneous lesions on the neck of mice in established disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the neck of mice. Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the neck of mice.

Figure 8: Treatment with Compound (I) suppressed erythema of cutaneous lesions on the ear of mice in established disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the ear of mice but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression of erythema of cutaneous lesions compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.

Figure 9: Treatment with Compound (I) suppressed total erythema of cutaneous lesions on mice in established disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice. Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice.

Figure 10: Treatment with Compound (I) showed suppression of the kidney injury marker proteinuria and urinary neutrophil gelatinase-associated lipocalin (NGAL) in established disease. Monotherapy with prednisolone or hydroxychloroquine showed suppression of the kidney injury marker proteinuria. The combination of Compound (I) with Prednisolone and the combination of Compound (I) with hydroxychloroquine showed increased suppression of the kidney injury marker proteinuria.

Figure 11: Treatment with Compound (I) showed suppression of the kidney injury marker urinary NGAL in established disease. Monotherapy with prednisolone or hydroxychloroquine showed suppression of the kidney injury marker urinary NGAL. The combination of Compound (I) with Prednisolone and the combination of Compound (I) with hydroxychloroquine showed increased suppression of the kidney injury marker urinary NGAL.

2. Combination Studies of Compound (I) with Prednisolone and Compound (I) with hydroxychloroquine (HCQ) in MRL/lpr Model of Lupus – Advanced Disease

Female MRL/lpr mice of 16 weeks of age were treated for 5 weeks. Mice were recruited when they showed group average of total skin lesions score as 2 to 2.5. Total skin lesions score includes cumulative score of Neck/Back, Face, Head and Ear lesions. Table 2 shows the treatments, doses, and number of mice in each treatment group.

TABLE 4

No.	Treatment	Dose (mg/kg)	% Survival
1	Vehicle	5mL/kg, qd	80
2	Compound (I)	0.25	93.3
3	Prednisolone	1	86.6
4	HCQ	100	100
5	Compound (I) + Prednisolone	0.25 + 1	100
6	Compound (I) + HCQ	0.25 + 100	100

7	Prednisolone	10	93.3
---	--------------	----	------

Figure 12: Treatment with Compound (I) suppressed the total number of cutaneous lesions in mice in advanced disease compared to treatment with vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of cutaneous lesions but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.

Figure 13: Treatment with Compound (I) suppressed erythema of cutaneous lesions on the neck of mice in advanced disease compared to vehicle. Monotherapy with prednisolone showed suppression of erythema of cutaneous lesions on the neck of mice. Treatment with the combination of Compound (I) + prednisolone showed suppression of erythema of cutaneous lesions on the neck of mice.

Figure 14: Treatment with Compound (I) suppressed erythema of cutaneous lesions on the neck of mice in advanced disease compared to vehicle. Monotherapy with hydroxychloroquine showed suppression of erythema of cutaneous lesions on the neck of mice. Treatment with the Compound (I) and treatment with the combination of Compound (I) + hydroxychloroquine showed increased suppression of erythema of cutaneous lesions on the neck of mice compared the treatment with hydroxychloroquine.

Figure 15: Treatment with Compound (I) suppressed erythema of cutaneous lesions on the ear of mice in advanced disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of erythema of cutaneous lesions on the ear of mice but less than treatment with Compound (I). Treatment with the combination of Compound (I) + prednisolone and the combination of Compound (I) and hydroxychloroquine showed increased suppression of erythema of cutaneous lesions compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.

Figure 16: Treatment with Compound (I) suppressed total erythema of cutaneous lesions on mice in advanced disease compared to vehicle. Monotherapy with prednisolone and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice. Treatment with the combination of Compound (I) + prednisolone and

the combination of Compound (I) and hydroxychloroquine showed suppression of total erythema of cutaneous lesions on mice compared to hydroxychloroquine and 1 mpk prednisolone monotherapies.

5


CLAIMS

What is claimed is:

- 5 1. A method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.

10


2. The method according to claim 1 wherein said TLR7 inhibitor is:



or a pharmaceutically acceptable salt thereof.

- 15 3. The method according to claim 1 comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof.

- 20 4. The method according to claim 3 wherein said TLR7 inhibitor is:




or a pharmaceutically acceptable salt thereof.

- 25 5. The method according to claim 1 comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a

pharmaceutically acceptable salt thereof.

6. The method according to claim 3 wherein said TLR7 inhibitor is:



5 or a pharmaceutically acceptable salt thereof.

7. The method according to Claim 1, wherein said therapeutically effective dose of said TLR7 inhibitor is from 0.1 to 100 mg per day.

10 8. The method according to Claim 1, wherein said therapeutically effective dose of said prednisolone is 0.5 to 50 mg per day.

9. The method according to Claim 1, wherein said therapeutically effective dose of said hydroxychloroquine is 1 to 20 mg per day.

15

10. The method according to claim 1 wherein said TLR7 inhibitor and said second agent are administered concurrently.

11. The method according to claim 1 wherein said TLR7 inhibitor and said second agent
20 are administered sequentially.

12. The method according to claim 1 wherein said TLR7 inhibitor is administered prior to administration of said second agent.

25 13. The method according to claim 1 wherein said second agent is administered prior to administration of said TLR7 inhibitor.




FIG. 1A

FIG. 1B

FIG. 1C




FIG. 1D

FIG. 1E




FIG. 2A

FIG. 2B




FIG. 2C




FIG. 3A

FIG. 3B

FIG. 3C




FIG. 4B




FIG. 4A




FIG. 5




FIG. 6




FIG. 8




FIG. 9

10/16




FIG. 10




FIG. 11




FIG. 15




FIG. 16

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2021/036740

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K31/437 A61K31/4706 A61K31/573 A61K45/06 A61P37/02
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TEBBE B ET AL: "HEUTIGE THERAPEUTISCHE ASPEKTE BEIM KUTANENLUPUS ERYTHEMATODES THERAPEUTIC ASPECTS OF CUTANEOUS LUPUS ERYTHEMATOSUS", DERMATOLOGISCHE MONATSSCHRIFT, JOHANN AMBRISIUS BARTZ, LEIPZIG, DE, DE, vol. 178, no. 3, 1 January 1992 (1992-01-01), pages 99-104, XP001033514, ISSN: 0011-9083 abstract	1-13
Y	WO 2018/005586 A1 (BRISTOL-MYERS SQUIBB COMPANY [US]) 4 January 2018 (2018-01-04) claims 9, 15	1-13

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 10 September 2021	Date of mailing of the international search report 21/09/2021
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Ansaldo, M
--	--------------------------------------

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2021/036740

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2018005586	A1	04-01-2018	AR 108905 A1 10-10-2018
			AU 2017287902 A1 14-02-2019
			BR 112018077119 A2 02-04-2019
			CA 3029620 A1 04-01-2018
			CL 2018003821 A1 22-04-2019
			CN 109641895 A 16-04-2019
			CO 2019000686 A2 19-02-2019
			EA 201990048 A1 31-05-2019
			EP 3478682 A1 08-05-2019
			IL 263961 A 31-01-2021
			JP 2019523241 A 22-08-2019
			KR 20190022735 A 06-03-2019
			PE 20190324 A1 05-03-2019
			SG 11201811590R A 30-01-2019
			TW 201805285 A 16-02-2018
			US 2018000790 A1 04-01-2018
			US 2018325874 A1 15-11-2018
			US 2020038374 A1 06-02-2020
			US 2021085651 A1 25-03-2021
			UY 37310 A 02-01-2018
			WO 2018005586 A1 04-01-2018
			ZA 201900571 B 28-10-2020
